World Health Organization (WHO), Geneva, Switzerland.
World Health Organization (WHO), Geneva, Switzerland.
Vaccine. 2019 Nov 28;37(50):7336-7345. doi: 10.1016/j.vaccine.2017.03.074. Epub 2017 Jun 21.
Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.
开发针对单纯疱疹病毒(HSV)的疫苗是全球性健康和生殖健康的一个重要目标。为了更准确地确定 HSV 感染的健康和经济负担,以及 HSV 疫苗的理论影响和成本效益,2015 年世界卫生组织召开了一次 HSV 疫苗影响建模专家协商会议。专家们审查了现有的基于模型的 HSV 感染估计和动态模型,以概述未来建模的关键需求,为 HSV 疫苗制定全面的商业案例和首选产品特征。本文总结了会议上与 HSV 负担、成本和疫苗影响建模相关的主要发现和讨论、开展这些模型所需的关键数据以及重要的模型组件和参数。